In silico therapy
Gliomas are the most frequent primary brain tumors, originating from glial cells –the neurons’ support cells-. Glioblastomas are the most frequent and malignant type. Low-grade gliomas are slowly growing infiltrative tumors and affect mostly young patients. No substantial therapeutic advances have been found in recent years. We build mathematical models of these tumors, search for the best treatment schedules and/or combinations of currently available therapies in-silico and develop hypotheses to be implemented in the clinics.
Cancer treatments and therapeutic interventions are subject to a great deal of uncertainty and involve a fair amount of trial and error. This reduces the potential clinical benefits and causes costs to shoot up. The outcome from currently available treatments can be improved, for instance by optimizing schedules, dosages, and combinations. Clinical trials could be designed virtually to produce better results with lower investment, what is referred to as in silico trials. This allow us to achieve optimal results in terms of patient survival and treatment toxicity.